Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions

Vaccine

Volumn 29, Issue 4, 2011, Pages 644-649

  Baldwin, Susan L ^a   Fox, Christopher B ^a   Pallansch, Mark A ^b   Coler, Rhea N ^a   Reed, Steven G ^a,c   Friede, Martin ^d  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c Immune Design Corp   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Adjuvant; IPV; Oil in water

Indexed keywords

ADJUVANT; NEUTRALIZING ANTIBODY; OIL; POLIOMYELITIS VACCINE; POLYSORBATE 80; SORBITAN TRIOLEATE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; DRUG POTENCY; EMULSION; FEMALE; IMMUNIZATION; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; RAT; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EMULSIONS; FEMALE; OILS; POLIOVIRUS VACCINES; RATS; RATS, WISTAR; VACCINATION; VACCINES, INACTIVATED; WATER;

EID: 78650542620     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.043     Document Type: Article

References (42)

1. Chumakov K. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 2008, 47:1587-1592.
2. Ehrenfeld E., Modlin J., Chumakov K. Future of polio vaccines. Expert Rev Vaccines 2009, 8:899-905.
3. John J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines 2009, 8:5-8.
4. Duchene M. Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals view. Biologicals 2006, 34:163-166.
5. WHO Global Action Plan: World Health Organization; 2010.
6. Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L., et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201:1344-1352.
7. Mohammed A.J., AlAwaidy S., Bawikar S., Padmamohan J., Elamir E., Shaban M.A., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Eng J Med 2010, 362:2351-2359.
8. Treanor J.J., Campbell J.D., Zangwell K.M., Rowe T., Wolf M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Eng J Med 2006, 354:1343-1351.
9. Keitel W., Groth N., Lattanzi M., Praus M., Hilbert A.K., Borkowski A., et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010, 28:840-848.
10. Baras B., Bouveret N., Devaster J.M., Fries L., Gillard P., Sanger R., et al. A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respi Viruses 2008, 2:251-260.
11. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., Drame M., et al. Priming with AS03A-adjuvanted H5 N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857.
12. Ott G., Van Nest G. Development of vaccine adjuvants: a historical perspective. Vaccine adjuvants and delivery systems 2007, 1-31. John Wiley & Sons, Hoboken, NJ. M. Singh (Ed.).
13. Stewart-Tull D.E.S. Freund's complete and incomplete adjuvants, preparation, and quality control standards for experimental laboratory animals use. Vaccine adjuvants: methods and protocols 2010, 59-72. Springer, New York. G. Davies (Ed.).
14. Fox C.B. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009, 14:3286-3312.
15. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., Hennig R. Safety of MF59 adjuvant. Vaccine 2008, 26:3209-3222.
16. Salk J.E., Bennett B.L., Lewis L.J., Ward E.N. Studies in human subjects on active immunization against poliomyelitis. J Am Med Assoc 1953, 151:1081-1098.
17. Salk J.E. Recent studies on immunization against poliomyelitis. Pediatrics 1953, 12:471-482.
18. Ivanov A.P., Dragunsky E.M., Chumakov K.M. 1,25-Dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 2006, 193:598-600.
19. Yang C., Shi H., Zhou J., Liang Y., Xu H. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 2009, 27:6558-6563.
20. O'Hagan D.T., Singh M. MF59: a safe and potent oil-in-water emulsion adjuvant. Vaccine adjuvants and delivery systems 2007, 115-129. John Wiley & Sons, Hoboken, NJ. M. Singh (Ed.).
21. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P. Van Nest G. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. Vaccine design: the subunit and adjuvant approach 1995, 277-296. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
22. Fox C.B., Anderson R.C., Dutill T.S., Goto Y., Reed S.G., Vedvick T. Monitoring the effects of component structure and source and formulation stability and adjuvant activity of oil-in-water emulsions. Colloid Surf B: Biointerfaces 2008, 65:98-105.
23. van Steenis G., van Wezel A.L., Sekhuis V.M. Potency testing of killed polio vaccine in rats. Dev Biol Stand 1981, 47:119-128.
24. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis 1997, 175:S215-S227.
25. Dowdle W.R., De Gourville E., Kew O.M., Pallansch M.A., Wood D.J. Polio eradication: the OPV paradox. Rev Med Virol 2003, 13:277-291.
26. Hovi T. Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 2001, 19:2268-2272.
27. Shahzad A., Kohler G. Inactivated Polio Vaccine (IPV): a strong candidate vaccine for achieving global polio eradication program. Vaccine 2009, 39:5293.
28. Halperin S.A., Tapiero B., Diaz-Mitoma F., Law B.J., Hoffenbach A., Zappacosta P.S., et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Vaccine 2009, 27:2540-2547.
29. White C., Halperin S.A., Scheifele D.W. Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines 2009, 8:831-840.
30. Ron D., Amir J., Livni G., Greenberg D., Abu-Abed J., Guy L., et al. Concomitant administration of a virosome-adjuvanted hepatitis A vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Ped Infect Dis J 2007, 26:787-793.
31. Coursaget P., Relyveld E.H., Brizard A., Frenkiel M.P., BFritzell B., Teulieres L., et al. Simultaneous injection of hepatitis B vaccine with BCG and killed poliovirus vaccine. Vaccine 1992, 10:319-321.
32. Cadoz M., Montagnon B., Yvonnet B., Xueref C., Vincent-Falquet J.C., Bandet R., et al. Lack of adjuvant effect of the pertussis component on IPV DTP-polio vaccine in children. Dev Biol Stand 1986, 65:153-158.
33. Pierard I, Duchene M. GSK Biologicals perspectives on the future IPV. Polio Immunization: Moving Forward; 2007 September 19-20. Bethesda, MD: NIH; 2007.
34. Henneberg G., Drescher J., Godgluck G., Grutzner L. Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in macaca mulatta. Am J Hyg 1962, 75:44-55.
35. Drescher J., Grutzner L., Godgluck G. Further investigations on the immunogenic activity of aqueous and aluminum oxide adsorbed inactivated poliovirus vaccines in Macaca mulatta. Am J Epidemiol 1967, 85:413-423.
36. Relyveld E.H. Preparation and use of calcium phosphate adsorbed vaccines. Dev Biol Stand 1986, 65:131-136.
37. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27:6291-6295.
38. Ross A.C. Vitamin A supplementation and retinoic acid treatment in the regulation of antibody responses in vivo. Vitam Hormon 2007, 75:197-222.
39. Cutler J.C., Lesesne L., Vaughn I. Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered. J Allergy 1962, 33:193-209.
40. Salk J., Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science 1977, 195:834-847.
41. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Eng J Med 2009, 361:2424-2435.
42. Bonnet M.C., Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008, 26:4978-4983.